InterMed Discovery

Tuesday, September 07, 2010

Pharmaceutical Products

Branch/ServicePharma Products
Title:Database driven ex-post evaluation of acyldepsipeptide LEAD class
Client description:R&D based pharma company focussed on development of antibacterial agents
Client’s challenge:
  • Lack of success in identification of antibacterial compounds through HTS.
  • Knows positive track record of NP in antibacterials, but has no in-house NP capabilities.
Client’s demand:
  • Needs alternative research approach in order to generate more antibacterial LEADs (high probability of success).
  • Specified criteria for agents:
    • Pre-defined in vivo-effect with relevant pathogens,
    • Feasibility of chemical post processing, 
    • IP-generation possible,
    • Accessibility of Natural Product or compound.
IMD’s strength:Expert system covering over 8000 NP AI compounds allowing broad analysis and generation of AI-projects meeting client’s requirements.
IMD’s assignment:Generation of novel research projects from known LEAD classes
IMD’s approach:
  • Database driven preselection of project candidates and portfolios according to predefined criteria
  • Candidate focussed in depth analysis of literature and patent situation and review of gathered data.
  • Feasibility evaluation based on availability and chemical manageability
  • Provision of compound
  • Broad evaluation of provided compounds regarding biological activity profile
  • Provision of compound in multi gram scale for chemical derivatization programs.
Results:

Provision of a LEAD candidate

 

Branch/ServicePharma Products
Title:Development of second and third generation proteasome inhibitors
Client description:R&D based pharma company seeking in-licensing opportunity
Client’s challenge:

Lack of corresponding development project

Client’s demand:

To fill late preclinical pipeline

IMD’s strength:IMD has proprietary portfolio of proteasome inhibitors in different stages of preclinical development
IMD’s assignment:Compiling of a development portfolio
IMD’s approach:
  • Provide qualified screening hits with a nanomolar activity at the proteasome target
  • Compiling of a portfolio with up to now four validated (structurally clarified) types of hit compounds
  • Broad biological tests (in vitro, in vivo)
  • Achieve in vivo proof of principle
  • Long-term in vivo study in indication cancer started
Results:

Development candidates for licensing/partnering